Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The current target of gout treatment is to reduce levels down to 6 mg/dL or less. SEL-212 is based on a uricase enzyme (pegadricase) that breaks down uric acid in the blood combined with an immune ...

If approved, Sobi and Selecta’s drug candidate will be a rival to Horizon Pharma’s FDA-approved Krystexxa (pegloticase), a uricase enzyme used to break down uric acid. The drug is administered ...

Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China ...

Notable advancements in 2023 include developments in uricase therapy, new xanthine oxidase inhibitors, and a class of medications that offer dual benefits for the control of type 2 diabetes ...

Most B cells produced in the bone marrow have some level of autoreactivity. Despite efforts of central tolerance to eliminate these cells, many escape to periphery, where in healthy individuals, they ...

Hyperuricemia is a metabolic disorder caused by an imbalance in the production and excretion of uric acid (UA), and is considered to be a risk factor for gout, obesity, chronic kidney disease, and ...

Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K. C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States ...

This revised version of the study is important, showing that age-related gut microbiota modulate uric acid metabolism through the NLRP3 inflammasome pathway and thereby regulate susceptibility to ...

This is an important study showing that age-related gut microbiota modulate uric acid metabolism through the NLRP3 inflammasome pathway and thereby regulate susceptibility to age-related gout. Several ...